Akebia Therapeutics Inc with TICKER NASDAQ:AKBA had its stock rating noted as ‘Coverage Initiated’ with the recommendation being set at ‘BUY’ today by analysts at Brean Capital. Akebia Therapeutics Inc are listed in the Health Care sector within NASDAQ. Brean Capital have set their target price at 18 USD on its stock. This would indicate that the analyst believes there is a potential upside of 129% from the opening price of 7.86 USD. Akebia Therapeutics Inc NASDAQ:AKBA has a 50 day moving average of 10.19 USD and a 200 Day Moving Average share price is recorded at 14.34 USD. The 52 week high for the stock is 31 USD while the year low stock price is currently 7.27 USD.
Akebia Therapeutics Inc NASDAQ:AKBA is a United States-based biopharmaceutical company, which is focused on the development of therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease. The Company’s product candidate, AKB-6548, is in a Phase-IIb clinical trial in patients with anemia secondary to chronic kidney disease who are not dependent on dialysis. AKB-6548 is being developed as a once-daily, oral therapy to inhibit hypoxia-inducible factor prolyl hydroxylase, which is expected to stabilize and increase levels of HIFα and improve the production of hemoglobin and red blood cells. AKB-6899 is its second hypoxia inducible factor-prolyl hydroxylase (HIF-PH) inhibitor product candidate.